Biopharma Daily Stock Updates - 09/22/21
$XBI $130.62 +0.28%
Covid Updates
$GILD -0.5% Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19 source
$INO -0.9% INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico source
$DVAX +26.5% COVID-19 Vaccine Developed by Clover Biopharmaceuticals Using Dynavax's CpG 1018 Adjuvant Meets Primary and Secondary Efficacy Endpoints in Global Phase 2/3 Trial source
$ARCT +1.5% Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern source
$BNTX -0.6% Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-For-Profit Price for Donation to Poorest Countries source
Pipeline Updates
$ASND -0.5% Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Forward Trial Demonstrating Continued Normalization and Stabilization of BMD Z-scores Between 26 and 58 Weeks source
$INCY -8.5% Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD) source
$RYTM +0.0% Rhythm Pharmaceuticals Presents New Data from Phase 2 and 3 Trials Evaluating Setmelanotide in Multiple Rare Genetic Diseases of Obesity at the 59th Annual ESPE Meeting source
$ENDP +9.0% Endo Launches First and Only Generic Version of Chantix® (varenicline) Tablets in the United States source
$SAVA -1.0% Cassava Sciences Announces Top-line Results of 12-month Interim Analysis from Open-label Study Evaluating Simufilam in Alzheimer’s Disease source
$CLRB +2.3% Preliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in Relapsed or Refractory Head and Neck Cancer source
$SCYX -0.4% SCYNEXIS Announces U.S. Availability of BREXAFEMME® (ibrexafungerp tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 Years source
$AKTX -2.3% Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress source
$RDUS +1.7% TYMLOS Label and Business Update source
$ONTX +28.6% Onconova Therapeutics Announces Encouraging Clinical Data Supporting The Anti-Cancer Activity Of Rigosertib-Nivolumab Combination In Advanced KRAS+ Non-Small Cell Lung Cancer source
$CYCN +0.3% Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator source
$ERAS -0.4% ERAS-007, A POTENTIAL BEST-IN-CLASS ERK1/2 INHIBITOR, WILL BE EVALUATED INITIALLY IN COMBINATIONS THAT COULD ADDRESS OVER HALF OF PATIENTS WITH COLORECTAL CANCER source
$FREQ -0.3% Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points source
$TSHA +2.5% TAYSHA RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN COMMISSION FOR TSHA-102 FOR THE TREATMENT OF RETT SYNDROME source
$CRVS -12.2% Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology and Infectious Disease source
Finance & Business Updates
$AMRN +3.1% AMARIN OUTLINES NEW GO-TO-MARKET STRATEGY TO ACCELERATE VASCEPA® (ICOSAPENT ETHYL) GROWTH IN U.S. source
$LPTX -4.7% Leap Therapeutics Announces Pricing of $90 million of Common Stock and Pre-Funded Warrants source
Posted by JM
Comments